• New options and opportunities in PrEP

    (A report back on Kavita Misra's session - New options and opportunities in PrEP: Impact of PrEP on drug resistance and acute HIV infection, New York City 2015-2017)

    Data on PrEP and associated resistance comes from safety and efficacy studies.  Mathematical modelling has suggested that any contribution from PrEP to resistance mutations would be very small and lower than if HIV infections were not averted. Concerns relate to starting PrEP during seroconversion and acquiring HIV and continuing the two drug regimen. 

     

  • Randomised Controlled Trial of Intrauterine Device Safety in women living with HIV

    (A report back on Catherine Todd's session - Randomised Controlled Trial of Intrauterine Device Safety in women living with HIV)

    Intrauterine contraceptive devices both Copper containg IUD (C-IUD) & progesterone containing IUD (LNG-IUD) are under utilised in HIV high prevalence settings.  LNG-IUD efficacy has been under contraversy with EFV containing ART regimens.